TÜBİTAK Turkey
TÜBİTAK 1507 — SME R&D Start-up, 2026 second call
The official 9 November extension notice sets the revised dates for the second 2026 SME R&D Start-up call. The programme supports SME R&D and innovation; the call documen…
TÜBİTAK · Turkey
TÜBİTAK 1812 Investment-Based Entrepreneurship Support Programme (BiGG Yatırım)
Programme — check the current round
- Deadline
- No fixed deadline
- Grant amount
- Investment ceilings for phases 2 and 3 are set by TÜBİTAK's board and announced in each…
- Funding rate
- Pre-seed and seed equity investment by TÜBİTAK-backed funds (shares in the company), not a cash grant
- Likely applicant types
- Companies, SMEs / start-ups, Universities & research From source categories or programme rules; the call decides.
- Funder
- TÜBİTAK
- Reference
- TÜBİTAK 1812
- Last checked
- 14 Nov 2026
Note: calls via accelerator programmes (check the current call).
The official texts for this programme are in Turkish.
Programme overview
Three phases: (1) accelerator programmes run by implementing organisations, which turn technology-based business ideas into business plans; (2) a pre-seed investment for concept design, feasibility, prototype or software development for up to 18 months; (3) a seed investment by a fund through a capital increase.
Who can apply
Students or graduates of a university associate, bachelor's, master's or doctoral programme at the time of applying to an accelerator call. People who already received Teknogirişim capital support or phase 2 of TÜBİTAK 1512/1812, or who are partners in an existing company when accepted to the accelerator, cannot apply.
Applicant categories are a starting point. The official call decides eligibility.
How to apply
- Apply to an accelerator programme call of an implementing organisation in PRODİS (phase 1).
- After completing the accelerator, submit the business plan in PRODİS (phase 2); the implementing organisation checks it first.
- Phase 2 and 3 plans are assessed by panels of at least three experts.
From the call text
- Who can apply
- Not stated in the call text we hold — check the official page
- Company stage
- Three phases: (1) accelerator programmes run by implementing organisations, which turn technology-based business ideas into business plans; (2) a pre-seed investment for concept design, feasibility, prototype or software development for up to 18 months; (3) a seed investment by a fund through a capital increase.
- Single applicant or consortium
- Not stated in the call text we hold — check the official page
- Where applicants must be based
- Not stated in the call text we hold — check the official page
- Where to apply
- Not stated in the call text we hold — check the official page
Where these facts come from
| Fact | Value | How we know | Taken from the source |
|---|---|---|---|
| Deadline | Unknown — not stated in the source we hold | unknown | — |
| Amount per applicant | Unknown — not stated in the source we hold | unknown | — |
| Total budget | Unknown — not stated in the source we hold | unknown | — |
| Funding rate | Pre-seed and seed equity investment by TÜBİTAK-backed funds (shares in the company), not a cash grant | checked by hand | 14 Nov 2026 |
| Who can apply | Students or graduates of a university associate, bachelor's, master's or doctoral programme at the time of applying to an accelerator call. People who already received Teknogirişim capital support or phase 2 of TÜBİTAK… | read from the official text | 14 Nov 2026 |
| Where to apply | Unknown — not stated in the source we hold | unknown | — |
Official sources
Facts on this page were read from the official page on 14 Nov 2026. The funder's own documents, including later amendments, always take precedence.
More from TÜBİTAK
TÜBİTAK Turkey
TÜBİTAK 1707 — Order-based SME R&D, 2026 third call
Order-based SME R&D support under the third 2026 call. TÜBİTAK’s extension notice gives the revised pre-registration and closing dates; applicants must consult the linked…
TÜBİTAK Turkey
EP PerMed 2027 — Cell and Gene Therapies for Personalised Medicine (Turkey participation)
The 2027 joint call supports development and validation of innovative cell and gene therapies for personalised human medicine. Approaches include somatic-cell therapies, …
TÜBİTAK Turkey
1831 Yeşil İnovasyon Teknoloji Mentörlük Çağrısı
1831 - Yeşil İnovasyon Teknoloji Mentörlük Çağrısı. Call listed on TÜBİTAK's official open-calls page.
TÜBİTAK Turkey Programme
TÜBİTAK 1001 — Scientific and Technological Research Projects
Supports scientifically based projects that generate knowledge, scientific interpretation or solutions to technological problems. Projects may last up to 36 months. This …